Bayer says Nexavar fails in breast cancer study
Friday, July 25, 2014 - 09:10
in Health & Medicine
FRANKFURT (Reuters) - German drugmaker Bayer said a Phase III trial of cancer drug Nexavar in patients with advanced breast cancer did not meet its primary endpoint of delaying the progression of the disease.